Bepotastine
Also sold as: Bepreve
Related Medications
These drugs share a pharmacologic classification but are NOT interchangeable. Listing here does not imply clinical equivalence. A physician must evaluate each drug individually for the patient's specific condition.
Classification: Histamine-1 Receptor Antagonist (source: RxClass/NLM)
- alcaftadineHistamine-1 Receptor AntagonistSame Class
- olopatadineHistamine-1 Receptor AntagonistSame Class
- azelastineHistamine-1 Receptor AntagonistSame Class
- acrivastineHistamine-1 Receptor AntagonistSame Class
- carbinoxamineHistamine-1 Receptor AntagonistSame Class
- cetirizineHistamine-1 Receptor AntagonistSame Class
- chlorpheniramineHistamine-1 Receptor AntagonistSame Class
- desloratadineHistamine-1 Receptor AntagonistSame Class
- diphenhydramineHistamine-1 Receptor AntagonistSame Class
- levocetirizineHistamine-1 Receptor AntagonistSame Class
- fexofenadineHistamine-1 Receptor AntagonistSame Class
Insurance Coverage User-Reported
No community coverage data yet for bepotastine.
Coverage data submission coming soon.
Drug Information
Mechanism of Action
12.1 Mechanism of Action Bepotastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.
Indications & Uses
1 INDICATIONS AND USAGE BEPREVE ® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H 1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis. BEPREVE is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis. ( 1 )
Dosage & Administration
2 DOSAGE AND ADMINISTRATION Instill one drop of BEPREVE into the affected eye(s) twice a day. Remove contact lenses prior to instillation of BEPREVE. • Instill one drop into the affected eye(s) twice a day. ( 2 ) • Remove contact lenses prior to instillation of BEPREVE. ( 2 )
Side Effects (Adverse Reactions)
6 ADVERSE REACTIONS The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions which occurred in 2-5% of subjects were eye irritation, headache, and nasopharyngitis. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The most common reported adverse reaction occurring in approximately 25% of subjects was a mild taste following instillation. Other adverse reactions occurring in 2-5% of subjects were eye irritation, headache, and nasopharyngitis. 6.2 Post-Marketing Experience Hypersensitivity reactions have been reported rarely during the post-marketing use of BEPREVE. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The hypersensitivity reactions may include itching, body rash, and swelling of lips, tongue and/or throat.
Contraindications
4 CONTRAINDICATIONS BEPREVE is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients [see Adverse Reactions ( 6.2 )] . Hypersensitivity to any component of this product. ( 4 )
Verify with Primary Sources
Always verify clinical information with authoritative sources.
Medical Disclaimer: Information on this page is sourced from FDA-approved labeling data and is for educational reference only. It does not constitute medical advice. This information does not establish a provider-patient relationship. Always verify with current prescribing information and consult a licensed healthcare professional before any clinical decision. Read full disclaimer.
Data sourced from RxNorm (NLM/NIH), FDA Orange Book, OpenFDA, DailyMed. Last updated: 2026-03-02.